All In Biotech

Drug Trial Radar · NCT06727734

Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception

Levonorgestrel-piroxicam Combination Versus Ulipristal Acetate for Emergency Contraception: a Randomised Double-blind Controlled Trial

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 980 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

980

Planned (sponsor's estimate)

Start

Jan 18, 2025

Primary completion

Sep 2027

Study completion Oct 2027

Sponsor

Lead sponsor
The University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Family Planning Association of Hong Kong
First posted
Dec 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the failure rate of the levonorgestrel (LNG)-piroxicam combination regimen versus ulipristal acetate (UPA) as emergency contraception (EC). The main questions it aims to answer are: 1. whether the LNG-piroxicam combination regimen has a lower failure rate than UPA for EC; 2. whether the LNG-piroxicam combination regimen has a higher percentage of pregnancies prevented than UPA for EC 3. whether there is any difference in the change in the subsequent menstrual cycle and adverse effect profile between the two regimens Participants will: 1. Take a single dose of either (i) LNG 1.5 mg plus piroxicam 40 mg and a placebo tablet resembling UPA, or (ii) UPA 30 mg plus placebo tablets resembling LNG and piroxicam. 2. Have a blood test for serum LH, oestradiol an progesterone. 3. Keep a diary of their vaginal bleeding episodes, adverse effects symptoms, any further acts of intercourse and the type of contraception used. 4. Have a follow-up either in person by phone about 1-2 weeks after the next expected menstruation. 5. If normal menstrual bleeding has not occurred by that time, a pregnancy test will be carried out.

Conditions

  • Contraception

Interventions

  • LevonorgestrelDrug

    Levonorgestrel 1.5 mg

  • PiroxicamDrug

    Piroxicam 40 mg

  • Ulipristal AcetateDrug

    Ulipristal 30 mg

  • Placebo - LNGDrug

    Placebo of levonorgestrel

  • Placebo - PiroxicamDrug

    Placebo of piroxicam

  • Placebo - UPADrug

    Placebo of ulipristal acetate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pregnancy rateTime frame: 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Family Planning Association of Hong Kong

    Hong Kong, Hong Kong · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.